HAD Digital (Oncology Home-Hospitalization) market product

MVP complete and delivered for Dr Kais Aldabbagh (CTCAE v5.0 grading, 19 API endpoints, shipped desktop exe). Build is done; the open investment question is the commercialisation path — licence, hosted service, or close out as delivered work.

Why we hold it: A finished, clinically serious MVP exists. As an investment, the remaining upside depends on choosing a commercialisation path with the owner-client: it needs regulatory (SaMD) decisions, hosting, and support commitments before it can earn recurring revenue.

⏱ 25d in stage (since 2026-09-05)🔄 last update 2026-09-18

MVP v1.0.0 delivered 2026-09-05: 24/24 capabilities, 94 tests green (37 Tier-1) — open question: licence, hosted, or close.

Reviewed

Problem

Home-hospitalised oncology patients are monitored through unstructured phone calls and paper; grade 1-2 toxicities go undetected until they become avoidable ED visits and re-admissions.

Purpose

Decide the asset's future by 2026-11-14 — one conversation with Dr Kais Aldabbagh either opens a revenue path (licence or hosted) or closes the record cleanly as delivered work.

🧭 Delivered asset, undecided future — zombie risk until ACT-001Stage marketBudget $0Next gate 2026-11-14Open actions 2

idea›concept›validation›build›market›revenue

Delivered asset, undecided future — zombie risk until ACT-001Decision point: Market → Revenue (or Close)in 45d (2026-11-14)

MVP v1.0.0 delivered 2026-09-05: 24/24 capabilities, 94 tests green (37 Tier-1) — open question: licence, hosted, or close.

✅ Proceed when

A paying path exists that covers SaMD + hosting + support with margin

⏸ Park when

Owner-client ambivalent — leave as completed work, revisit on trigger

⛔ Kill when

Regulatory burden makes SME commercialisation uneconomic — record lessons to 08_Reusable_Knowledge and close

💡 Advisor: 2026-09-12: Do not let this drift in 'finished but undecided'. One conversation either opens a revenue path or cleanly closes the record. The build cost is sunk; only forward costs matter to the decision.

market

Stage

25d in stage

Budget

Portfolio record (investment block) + HAD_Digital_Journey_to_Market_France.md (conditional EUR scenarios)

Open actions

owner-owed

High/critical risks

of 6 total

Unvalidated assumptions

of 5

Open issues

live

🗺️ Engagement Flow — Stages, Gate & Exits

DoneCurrentPlannedGatePark (dashed)Kill (dashed)

⚠️ What could sink it — top risks

RSK-01Regulatory (SaMD qualification): auto-grading + urgent/emergency alerting meets the MDSW definition — Class IIa minimum under MDR Rule 11; deploying or selling without CE marking is an offence in France.high 16

RSK-02Data security: the MVP stores health data in local SQLite with no MFA or encryption — not a deployable architecture for real patients.high 12

RSK-03Low adoption by clinicians and patients — the workflow changes daily practice for 8 roles.med 9

✅ What to do next

ACT-001Talk to Dr Kais Aldabbagh: is there appetite to commercialise (licence/hosted) or is this delivered work?2026-10-17

ACT-002If commercialising: scope SaMD regulatory pathway + hosting costs into a business_plan.json (v4.0 governance)2026-11-14

Gate criteria — Market → Revenue (or Close)

Owner-client conversation held
Path chosen: licence / hosted service / close as delivered work
If continuing: business plan with regulatory + hosting costs approved

🔍 Dig deeper

⚡ Execution 🗺️ Plan & Actions 🧠 Intelligence 💰 Value & Money 🎯 Strategy 🧰 Resources 📜 Charter

📜Charter

Unstructured home monitoring of chemo toxicity causes avoidable escalations; the MVP solves the workflow, the business path is unsolved. · Convert a delivered, tested clinical MVP into a deliberate commercialisation decision — or a proud close — using one owner-client conversation instead of drift.

🗣 Problem Statement

In hospitalisation a domicile (HAD) oncology, toxicity monitoring runs on phone calls and paper forms: the oncologist, HAD nurse, community nurse and GP each see different information at different times, and grade 1-2 toxicities are typically caught only at escalation. The consequences are avoidable ED visits and re-hospitalisations plus heavy clinician transcription burden. The delivered MVP solves the workflow (structured CTCAE v5.0 capture, rule-based auto-grading, tiered alerts, shared timeline); the unsolved problem is commercial — no path has been chosen and the asset currently earns nothing.

Pain points (severity)

Grade 1-2 toxicity detected late — avoidable ED visits and re-admissions (MVP_PLAN O4 target: ≥20% reduction)

5/5

Care team sees different information at different times — no shared timeline across oncologist, nurses, GP, pharmacist

4/5

Manual transcription of symptom reports into medical records — clinician admin burden (O5 target: ≥30% reduction)

3/5

Portfolio level: a finished asset with no next decision consumes attention without producing evidence (zombie risk)

3/5

Evidence & sources

MVP_PLAN.md problem table: unstructured phone/paper monitoring, fragmented information silos, delayed grade 1-2 detection → avoidable ED visits and re-hospitalisations
Project_Status.md (v1.0.0, 2026-09-05): 24/24 capabilities, 19 API endpoints, 10-table SQLite, 12 CTCAE terms, 8 roles, French patient guidance, 18 MB standalone .exe
TEST_READY.md (2026-09-05): 94-test pytest suite across 5 tiers (Tier 1: 37 tests) + 8-step acceptance script, 100% pass in under 9 seconds; 2 defects found and fixed during testing
Journey to Market France (2026-09-06): auto-grading + alerting meets the MDSW definition (MDCG 2019-11) → Class IIa minimum under MDR Rule 11; oncology télésurveillance forfaits of EUR 28-70/patient/month inscribed 2024-25; no competitor owns the HAD-specific workflow

🎯 Purpose & Objectives

Convert a delivered, tested clinical MVP into a deliberate commercialisation decision — or a proud close — using one owner-client conversation instead of drift.

Objectives

OBJ-1

Deliver the MVP to specification for Dr Kais Aldabbagh

Measure: 24/24 capabilities; 94/94 tests green (37 Tier-1); v1.0.0 baselined 2026-09-05

met

OBJ-2

Hold the commercialisation conversation (ACT-001)

Measure: Conversation with Dr Kais Aldabbagh held by 2026-10-17

planned

OBJ-3

Choose the path: licence / hosted service / close as delivered work

Measure: Decision recorded; gate due 2026-11-14

planned

OBJ-4

If continuing: scope SaMD regulatory pathway + hosting costs (ACT-002)

Measure: business_plan.json with regulatory + hosting costs approved

planned

OBJ-5

If closing: capture lessons and close the record cleanly

Measure: Lessons recorded to 08_Reusable_Knowledge; stage → closed

planned

📐 Scope

The delivered MVP plus the commercialisation decision. Everything forward-looking (SaaS rebuild, CE marking, clinical pilots) is conditional on the ACT-001/002 outcome and belongs to a future business plan, not this record.

✅ In scope

MVP v1.0.0 as delivered and baselined (2026-09-05)
The commercialisation decision (licence vs hosted vs close)
If continuing: SaMD regulatory + hosting cost scoping (ACT-002)
Owner-client relationship (Dr Kais Aldabbagh)

⛔ Out of scope

Production SaaS rebuild on HDS-certified hosting (post-decision)
CE-marking / Notified Body engagement (Journey stages 2-6)
Clinical pilot or PMCF study
Connected devices, DMP interoperability, ML risk-scoring (spec S4.2 / V2 items)
Billing / PMSI workflows

Constraints

MVP is explicitly a demo artifact — local SQLite on patient machines is not a deployable health-data architecture (Journey to Market, stage 2)Auto-grading + clinician alerting meets the MDSW definition → Class IIa minimum under MDR Rule 11; selling an unclassified device in France is an offenceEUDAMED registration mandatory since 28 May 2026 before placing a device on the EU marketZero new capital unless a commercialisation path is chosen (record: capital at risk)

💰Value & Money

A CTCAE-native toxicity watchtower built for the HAD oncology workflow — structured capture, rule-based auto-grading, tiered alerts and a shared care timeline — existing today as a finished, tested MVP, with clinical-founder authenticity competitors cannot copy.

💎 Value Proposition

Value drivers

Pricing anchor if licensed (EUR)

EUR 28-70 / patient / month

French télésurveillance forfaits (art. L.162-52 CSS) inscribed for oncology devices 2024-25 (Continuum+, Cureety, Satelia); playbook prices the patient fee at EUR 15-35 inside the forfait.

Per-site platform licence if licensed (EUR)

EUR 8k-20k / site / year

Sized so a year-1 pilot fits under the EUR 40k HT simplified-procurement threshold French hospitals use.

Clinical value target

≥20% re-admissions

MVP_PLAN O4 / MOE-4: reduction in unplanned re-hospitalisations vs baseline, to be measured in a post-CE pilot.

Delivered asset value today

$0 recurring

No revenue; the MVP's current value is the option it creates for the ACT-001 conversation.

Build cost to date

$0 cash

Record investment block: cash_committed 0, cash_spent 0 — build was agent/founder time.

Revenue model: None yet. If commercialised per the playbook: per-site annual licence + per-active-patient monthly fee anchored to the French télésurveillance forfaits. Otherwise none — completed client work.

⚖️ Cost–Benefit Analysis

Sunk build cost is $0 cash; every forward cost is conditional on the path chosen at the gate. The full France CE-mark journey is estimated at EUR 150k-300k over ~24 months to first paid licences — only relevant if the owner-client commits.

PaybackTo be quantified — depends entirely on the path chosen at the 2026-11-14 gate

Costs vs benefits (scaled)

MVP build & delivery time sunk — delivered 2026-09-05

Commercialisation decision (conversation + scoping) time 2026-09 to 2026-11

If continuing: IP lockdown + SASU creation (EUR, midpoint of EUR 315-2,500) cash conditional — Journey stages 0-1, months 0-2

1408

If continuing: CE-mark gauntlet via Notified Body (EUR, midpoint of EUR 100k-250k) cash conditional — 18-30 months

175000

If continuing: full journey to first paid licences (EUR, midpoint of EUR 150k-300k) cash conditional — ~24 months; grant-coverable (Bpifrance i-Lab up to EUR 600k)

225000

Revenue to date to date — completed client work

If licensed: per-site EUR 8k-20k/yr + per-patient EUR 15-35/month (scenario) ~24 months out, post-CE — to be quantified

Method & assumptions

EUR figures are the owner's France market playbook estimates (Journey to Market, 2026-09-06) shown at range midpoints; they are scenario costs, not commitments. No AUD conversion applied because nothing is committed. NDIS-style payback math is impossible until a path exists.

🎯Strategy

Sunk-cost discipline: the build is delivered and paid for; only forward costs matter to the decision. Hold exactly one conversation with the owner-client by 2026-10-17 and let the answer pick the path — licence (France playbook), hosted SaaS (EUR 150k-300k CE journey, grant-coverable), or close as completed client work. The rejected path is drifting.

🧭 High-Level Strategy

📍 Positioning

If commercialised: a CTCAE-native toxicity watchtower for hospitalisation a domicile, built by an oncologist, graded for the ward, reimbursable (playbook positioning line). Today: delivered client work awaiting a decision.

🏰 Moat / defensibility

None operative. Potential moats if the France path is taken: clinical founder authenticity, the unowned HAD-specific workflow position, and the CE / ISO 13485 regulatory barrier — the barrier is the moat, and it costs EUR 150k-300k to build.

Strategic options

Decide by conversation (ACT-001 by 2026-10-17) adopted

One hour of owner time resolves the portfolio's cleanest zombie risk.

Licence per-site + per-patient in France watching

Real reimbursement anchors (EUR 28-70 forfaits) exist; requires Class IIa CE mark — 18-30 months and EUR 100k-250k.

Hosted SaaS funded by grants (i-Lab up to EUR 600k) watching

Highest upside and longest path; depends entirely on owner-client commitment.

Close as delivered work watching

Zero further cost, forfeits the option value — but delivered work is a win.

Drift undecided rejected

Consumes attention without producing evidence.

🚦 Decision Rules (pre-committed)

✅ Proceed when

A paying path exists that covers SaMD + hosting + support with margin

⏸ Park when

Owner-client ambivalent — leave as completed work, revisit on trigger

⛔ Kill when

Regulatory burden makes SME commercialisation uneconomic — record lessons to 08_Reusable_Knowledge and close

💡 Advisor note

2026-09-12: Do not let this drift in 'finished but undecided'. One conversation either opens a revenue path or cleanly closes the record. The build cost is sunk; only forward costs matter to the decision.

🗺️Plan & Actualisation4

4 actualisation steps · 0 done · 2 active · next: Hold the ACT-001 conversation with Dr Kais Aldabbagh

🧭 Dependency Map — Steps to Actualisation

Arrows show what each step needs before it can start; the longest left-to-right chain is the critical path.

DoneCurrentPlannedGate

📅 Stages & Time

Sep 2026Oct 2026Nov 2026Dec 2026

Specification & MVP build (v1.0.0)

2026-09

Verification & baseline (94 tests green, .exe shipped)

2026-09

Market-stage hold & portfolio import

2026-09 → 2026-10

Commercialisation decision window (ACT-001/002)

2026-10 → 2026-11

Commercialisation decision — if GO: business plan & pathway setup

2026-11 → 2026-12

🪜 Steps to Actualisation

Click any step to expand its sub-steps, owner and dependencies.

Hold the ACT-001 conversation with Dr Kais Aldabbagh active

Phase: Commercialisation decisionOwner: Zaid

Appetite check: licence, hosted service, or completed work?
Due 2026-10-17

If commercialising: scope SaMD pathway + hosting costs (ACT-002) planned

Phase: Commercialisation decisionOwner: Zaid + Dr Kais AldabbaghDepends on: S1

business_plan.json under v4.0 governance
Entry point = Journey stages 0-1 (IP lockdown, SASU)
Due 2026-11-14

If no appetite: close the record with pride planned

Phase: Commercialisation decisionOwner: ZaidDepends on: S1

Lessons to 08_Reusable_Knowledge
Stage → closed; delivered work is a win

Keep the asset verified and protected while undecided active

Phase: Market-stage holdOwner: Zaid

Test suite stays green
No unprotected demos of specs/deck if IP matters (Journey stage 0 discipline)

🔁 Development Process

Governance-standard staged delivery: AI Project Governance Standard v3.9, specification-first (S4.1 scope), multi-agent build tracks with challenger/auditor gates, and a 5-tier E2E test suite as the release gate.

Specification›MVP build›Verification›Baseline & handover›Market-stage hold›Commercialisation decision

Specification

Original request and spec: standalone .exe, role-based auth, toxicity reporting, care timeline.

ORIGINAL_REQUEST.md
HAD_Digital_Specifications.docx
MVP_PLAN.md

MVP build

Multi-agent build (orchestrator, workers, reviewers, sentinel) against the governance standard.

MVP application (12 Python files, ~2,500 LOC)
SQLite schema (10 tables)
19-endpoint API

Verification

5-tier pytest suite plus zero-dependency acceptance script; 2 defects found, escalated and fixed during testing.

94/94 tests green in under 9s (37 Tier-1)
verify_mvp.py acceptance script

Baseline & handover

v1.0.0 packaged as an 18 MB standalone Windows .exe; transfer pack with prohibitions and open items.

HAD Digital.exe
00_Handover transfer pack
Registers: 7 decisions, 5 risks

Market-stage hold

Asset delivered and held at market stage: keep the test suite green and IP discipline while the commercialisation path is undecided.

94-test suite kept green
IP-disciplined demo handling

Commercialisation decision

Owner-client conversation, then licence / hosted / close; business plan if continuing.

ACT-001 outcome
business_plan.json if continuing

🧰Resources

The build was agent-led under governance; from here this record needs one conversation, not build capacity.

💵 Budget

Total budget: $0 · Source: Portfolio record (investment block) + HAD_Digital_Journey_to_Market_France.md (conditional EUR scenarios)

Allocation by phase (bar = allocated, amber = spent)

MVP build & delivery (sunk)

— / —

Decision window

— / —

If continuing: France journey (EUR scenario)

— / —

Playbook scenario costs, none committed: stage 0 IP EUR 15-1,500; SASU EUR 300-1,000; medical-device-grade build EUR 30k-80k; data protection EUR 5k-15k; CE EUR 60k-150k; clinical EUR 20k-60k; market access EUR 20k-80k; NB fees EUR 20k-60k initial + EUR 10k-25k/yr. Bars show 0 because nothing is allocated yet. Ranges overlap the bundled cost lines above: the CE-mark gauntlet line (EUR 100k-250k, in cost_benefit) already includes NB fees (EUR 20k-60k), and the medical-device-grade build (EUR 30k-80k) includes data protection (EUR 5k-15k). Per-stage ranges therefore overlap and must not be summed; the journey total remains the playbook's own EUR 150k-300k.

🧾 Investment Ledger

Cash committed ($)

total committed

Cash spent ($)

to date

Hours invested

founder time

Capital at risk: Zero new capital unless a commercialisation path is chosen; then hosting + SaMD compliance costs.

👥 People & Tools

People

Name	Role	Commitment	h/week
Zaid Al Dabbag	Project owner & governance authority (all project decisions per GOV-A1.5)	One conversation + scoping if continuing	0.5
Dr Kais Aldabbagh	Client / concept originator / clinical authority	Commercialisation decision + clinical review of grading rules	0
AI advisor (ZCode)	Advisor / portfolio review	Fortnightly flip-through (portfolio overhead)	0

Tools

Tool	Purpose	Cost
HAD Digital.exe (18 MB standalone)	Demo / training sandbox — to be labelled non-clinical if shown	built — $0 cash
94-test pytest suite + acceptance script	Regression safety while the record is held	built
Journey-to-Market playbook (France)	The commercialisation playbook if the path opens	done — advisor time

🤝 Stakeholders

Keep informed · high interest / low influence

AI advisor (ZCode) champion

Manage closely · high / high

Dr Kais Aldabbagh championZaid Al Dabbag champion

Monitor · low / low

Care-team roles (oncologist, HAD nurse, GP, pharmacist) neutralFuture HAD structures (prospective customers) neutral

Keep satisfied · low interest / high influence

Notified Body / ANSM (prospective) neutral

Full stakeholder register (6)

Name	Role	Interest	Influence	Needs / notes
Dr Kais Aldabbagh	Client / concept originator / clinical authority	high	high	Decide commercialisation appetite (ACT-001); review grading rules and French guidance content
Zaid Al Dabbag	Project owner / governance authority	high	high	A clean decision — open a revenue path or close the record; no drift
Care-team roles (oncologist, HAD nurse, GP, pharmacist)	Future users	med	low	Workflow fit; user testing before any pilot
Notified Body / ANSM (prospective)	Regulators if the EU path is taken	low	high	Class IIa conformity file, EUDAMED registration, UDI
Future HAD structures (prospective customers)	Buyers / pilot sites	med	med	Evidence: PMCF data, re-admission outcomes, sub-EUR-40k entry pricing
AI advisor (ZCode)	Advisor	high	low	One conversation booked this month; honest close if no appetite

🧠Intelligence

6 risks (2 high/critical) · 4 upside opportunities · 5 assumptions · 2 open issues

⚠️ Risk Register

RSK-01

RSK-06

RSK-03RSK-04

RSK-02

RSK-05

I1I2I3I4I5

L = likelihood, I = impact (1–5). Tint = severity band: low / medium / high (L×I ≥ 12) / critical (≥ 20).

Full risk register (6)

ID	Risk	Category	L/I	Severity	Mitigation	Owner	Status
`RSK-01`	Regulatory (SaMD qualification): auto-grading + urgent/emergency alerting meets the MDSW definition — Class IIa minimum under MDR Rule 11; deploying or selling without CE marking is an offence in France.	regulatory	4/4	high	Engage regulatory counsel before any pilot; write the intended-purpose/classification memo anticipating an IIb challenge (Journey stage 2.3).	Dr Kais Aldabbagh	open
`RSK-02`	Data security: the MVP stores health data in local SQLite with no MFA or encryption — not a deployable architecture for real patients.	security	3/4	high	Any real-data path requires SaaS on HDS-certified hosting, MFA and encryption (register RSK-002 + Journey stage 2).	Technical Lead (unassigned)	open
`RSK-03`	Low adoption by clinicians and patients — the workflow changes daily practice for 8 roles.	adoption	3/3	med	User testing with real patients and clinicians; iterative design (register RSK-003).	Dr Kais Aldabbagh	open
`RSK-04`	Data quality: patient self-report can mis-grade symptoms.	clinical	3/3	med	Clinician confirmation required for Grade >= 2 (register RSK-004).	Dr Kais Aldabbagh	open
`RSK-05`	IP protection: ideas and CTCAE mapping logic are not copyright-protected, and AI-authored code stretches have weak copyright.	legal	2/4	med	Journey stage 0: e-Soleau deposit (EUR 15), NDA discipline before demos, documented human authorship, patent decision this month if continuing.	Dr Kais Aldabbagh	open
`RSK-06`	Portfolio zombie risk: the record drifts as finished-but-undecided, consuming attention without producing evidence.	portfolio	3/2	med	ACT-001 by 2026-10-17; if no appetite, close the record with pride (advisor note, 2026-09-12).	Zaid	mitigating

🌱 Upside Opportunities

later

Licence path anchored to French forfaits

Per-site EUR 8k-20k/yr + EUR 15-35/active patient/month inside EUR 28-70 télésurveillance forfaits; hospitals buy under the EUR 40k simplified procedure.

Upside: med · Effort: high

good

Hosted SaaS with grant-funded CE journey

Bpifrance i-Lab grants up to EUR 600k (60% of costs) could fund the EUR 150k-300k journey; PECAN / forfait innovation provide early coverage routes.

Upside: high · Effort: high

good

Close cleanly as delivered work

A delivered, tested MVP for a client is a portfolio win; lessons feed 08_Reusable_Knowledge and the EMS Suite product track at near-zero cost.

Upside: low · Effort: low

good

Reusable delivery pattern

The governance-standard + multi-agent + 5-tier-test delivery pattern proven here is reusable for the next build in the portfolio.

Upside: med · Effort: low

🧩 Assumptions

ASM-01

Dr Kais Aldabbagh has appetite to commercialise (licence or hosted).

Validation: ACT-001 conversation by 2026-10-17.

unvalidated

ASM-02

The delivered MVP is a credible demo/sales artifact for that conversation.

Validation: 24/24 capabilities, 94/94 tests green (37 Tier-1), transfer pack on file.

confirmed

ASM-03

France is the relevant market if commercialised (French guidance content, HAD workflow, EU playbook).

Validation: Confirm target market in the ACT-001 conversation.

unvalidated

ASM-04

Télésurveillance forfaits EUR 28-70 remain the pricing anchor.

Validation: Check the latest art. L.162-52 arrêtés / HAS inscriptions before any pricing.

unvalidated

ASM-05

No cash is required while the record is held open.

Validation: Record investment block: $0 committed, $0 spent.

confirmed

🔴 Issue Log (live)

ID	Issue	Impact	Raised	Status	Resolution
`ISS-01`	Commercialisation decision not made (DEC-008 not yet opened per the record KPI).	Record cannot leave the market stage; gate due 2026-11-14	2026-09-12	open
`ISS-02`	Record KPI 'Tests passing' showed 37 while TEST_READY.md reports 94/94 — 37 is the Tier-1 subset, not the suite total.	Test-count figure differed between portfolio record and project source	2026-09-12	resolved	Unified 2026-09-13: KPI and dossier now both state 94 (37 Tier-1).

⚡Execution

Stage KPIs · next gate: Market → Revenue (or Close) (due 2026-11-14) · 2 open owner actions · full progress log.

📊 Stage KPIs

KPI	Current	Target
Capabilities delivered	24 / 24	kept at 100%
Tests passing	94 (37 Tier-1)	green at every release
Open risks	5 project + 1 portfolio (mitigating)	owned before commercialisation
Commercialisation decision	Not made	DEC-008 opened and closed

🚪 Next Gate — Market → Revenue (or Close)

Due: in 45d (2026-11-14)

Owner-client conversation held
Path chosen: licence / hosted service / close as delivered work
If continuing: business plan with regulatory + hosting costs approved

✅ Next Steps & Actions

ID	Action	Due	Status
`ACT-001`	Talk to Dr Kais Aldabbagh: is there appetite to commercialise (licence/hosted) or is this delivered work?	2026-10-17	open
`ACT-002`	If commercialising: scope SaMD regulatory pathway + hosting costs into a business_plan.json (v4.0 governance)	2026-11-14	open

🕘 Progress Log (newest first)

2026-09-18 market

Dossier review pass (program OBJ-3): budget notes annotated so stage ranges no longer read as contradicting the EUR 150k-300k journey total, risk KPI now counts all 6 rendered risks, market-hold phase outputs added.

2026-09-15 market

Flip-through: zombie-risk record by design — one conversation with Dr Aldabbagh (due 17 Oct) is all that separates a commercialisation path from a clean, proud close as delivered work. Nothing else owed.

2026-09-12 market

Imported into portfolio tracker. MVP v1.0.0 complete 5 Sep 2026 and delivered; 7 project decisions closed. Portfolio action: open a commercialisation decision (licence vs hosted vs archive as completed client work).

🔗 Links

Clinical dashboard (portal tab) Project status Decision log

‹ Engineering Management Suite (Product)▦ All 9 AI Consultancy for SMB ›